AN EXPERIENCE OF SERELAXINE USE FOR ACUTE HEART FAILURE IN PATIENTS WITH ONCOHEMATOLOGICAL DISEASES

Aim. To assess efficacy of serelaxine in ACF caused by cardiotoxic effect of cytostatic therapy.

Material and methods. Serelaxine is a recombinant human relaxine-2, having hemodynamic and pleiotropic organoprotective effects. The data on the drug efficacy for one or other cause of ACF is non-sufficient. In single-center observational study there is an experience presented of serelaxine in pulmonary oedema, developed as complication of polychemotherapy (PCT) in oncohematological diseases.

Results. The use of serelaxine in addition to the standard treatment led to successful cessation of pulmonary oedema, stabilization of hemodynamics and of blood gases, therefore to completion of full PCT program.

Conclusion. The first clinical experience presented has shown efficacy of serelaxine in ACF due to cardiotoxic action of PCT in oncohematological patients. Further clinical trials are aimfull in this category of patients.  

1. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.

2. Mareev VYu, Ageev FT, Arutyunov GP, et al. National recommendations PRAS, CSC and REMOT for the diagnosis and treatment of CHF (fourth revision). Heart Failure 2013; 14 (7): 379-472). Russian (Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная Недостаточность 2013; 14 (7): 379-472).

3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: e240-327.

4. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.

5. Dschietzig TB. Recombinant human relaxin-2: (how) can a pregnancy hormone save lives in acute heart failure? Am J Cardiovasc Drugs 2014; 14: 343-55.

6. Cotter G, Felker GM, Adams KF, et al. The pathophysiology of acute heart failure—is it all about fluid accumulation? Am Heart J 2008; 155: 9-18.

7. Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure—re¬distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008; 10: 165-9.

8. Summers RL, Amsterdam E. Pathophysiology of acute decompensated heart failure. Heart Fail Clin 2009; 5: 9-17.

9. Cotter G, Milo O, Davison BA. Increased mortality after an acute heart failure episode: new pathophysiological insights from the RELAX-AHF study and beyond. Curr Heart Fail Rep 2014; 11: 19-30.

10. Bennett RG. Relaxin and its role in the development and treatment of fibrosis. Transl Res 2009; 154: 1-6.

11. Link A, Poss J, Bohm M. Pharmacotherapy of acute heart failure: update and perspectives. Dtsch Med Wochenschr 2012; 137: 1126-9.

12. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.

13. Diez J. Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions. Am J Cardiovasc Drugs 2014; 14: 275-85.

14. Castel M, Despas F, Modesto A, et al. Cardotoxicity of chemotherapy. Presse Med 2012; 6: 21-4.

15. Morandi P, Ruffini PA, Benvenuto GM, et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005; 35: 323-34.